

# TABLE OF CONTENTS

<b>Pediatric Oncology I</b>	<b>1</b>	<b>Clinical and Practice Updates I</b>	<b>65</b>
Pediatric Oncology I Panel.....	3	Clinical and Practice Updates Panel.....	67
<b>Pediatric Cancer Treatment Development</b>		<b>Recorded Webcast: Handling and Preparation of Chemotherapy</b>	
<i>By Cynthia Jiles, R.Ph., BSPHarm; and Eileen Wu, Pharm.D.</i>		<i>By Devona Williams, Pharm.D., BCOP; and Rebecca Deoras, Pharm.D., BCPPS</i>	
Introduction .....	7	On-Demand Webcast .....	71
Therapeutic Achievements .....	11	References .....	72
Complements to Clinical Research .....	17	Self-Assessment Questions.....	73
New Directions for Pediatric Oncology Research .....	19	<b>Recorded Webcast: Educating Patients and Caregivers on Handling Hazardous Drugs</b>	
Conclusion .....	20	<i>By Nicole Arwood, Pharm.D., BCPPS</i>	
References .....	21	On-Demand Webcast .....	77
Self-Assessment Questions.....	23	References .....	78
<b>Asparaginase Monitoring in Patients with Leukemia</b>		Self-Assessment Questions.....	79
<i>By Tamara MacDonald, Pharm.D.</i>		<b>Recorded Webcast: Antimicrobial Prophylaxis for the Pediatric Oncology Patient</b>	
Introduction .....	27	<i>By Jennifer L. Pauley, Pharm.D., BCPS, BCOP; and Shane Cross, Pharm.D., BCPS</i>	
Currently Available Asparaginase Formulation .....	28	On-Demand Webcast .....	83
Quantitative Laboratory Methods of Measuring Asparaginase Activity .....	30	References .....	84
Therapeutic Drug Monitoring of Asparaginase .....	31	Self-Assessment Questions.....	86
Mechanisms of Asparaginase Resistance .....	32		
Hypersensitivity Reactions to Asparaginase: Type, Incidence and Classification .....	33		
Factors that May Influence Asparaginase Activity .....	34		
Clinical Trial Outcomes .....	35		
Implications for Clinical Practice .....	36		
The Pharmacist's Role .....	36		
Gaps in Research .....	36		
Conclusion .....	36		
References .....	37		
Self-Assessment Questions.....	39		
<b>Biosimilar Use in Pediatric Oncology</b>			
<i>By Rachel Langley, Pharm.D., BCPPS</i>			
Introduction and Background .....	43		
Pathway for the Regulatory Approval of Biosimilar Agents .....	46		
Role of G-CSF in Clinical Practice .....	48		
Hurdles to Implementing Use of Biosimilar Filgrastim in the Pediatric Setting .....	56		
Conclusion .....	58		
References .....	58		
Self-Assessment Questions.....	60		